Everolimus for Advanced Pancreatic Neuroendocrine Tumors

BACKGROUND: Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study. METHODS: We randomly assigned 410 pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yao, James C., Shah, Manisha H., Ito, Tetsuhide, Bohas, Catherine Lombard, Wolin, Edward M., Van Cutsem, Eric, Hobday, Timothy J., Okusaka, Takuji, Capdevila, Jaume, de Vries, Elisabeth G.E., Tomassetti, Paola, Pavel, Marianne E., Hoosen, Sakina, Haas, Tomas, Lincy, Jeremie, Lebwohl, David, Öberg, Kjell
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208619/
https://ncbi.nlm.nih.gov/pubmed/21306238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1009290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados